Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 12(1): 19978, 2022 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-36404312

RESUMEN

The eruption of the Hunga-Tonga volcano in the South Pacific Ocean on January 15, 2022, at about 4:15 UTC, generated a violent explosion, which created atmospheric pressure disturbances in the form of Rayleigh-Lamb waves detected all over the globe. Here we discuss the observation of the Hunga-Tonga shock-wave performed at the Ny-Ålesund Research Station on the Spitsbergen island, by the detectors of the PolarquEEEst experiment and their ancillary sensors. Online pressure data as well as the results of dedicated offline analysis are presented and discussed in details. Results include wave arrival times, wave amplitude measurements and wave velocity calculation. We observed five passages of the shock wave with a significance larger than 3 [Formula: see text] and an amplitude up to 1 hPa. The average propagation velocity resulted to be (308 ± 0.6) m/s. Possible effects of the atmospheric pressure variation associated with the shock-wave multiple passages on the cosmic-ray rate at ground level are also investigated. We did not find any significant evidence of this effect.

2.
Biomed Res Int ; 2018: 5095673, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30420965

RESUMEN

The present study aimed to evaluate the effects of two types of 9-month adapted physical activity (APA) program, based on a muscle reinforcement training and a postural training, respectively, on muscle mass, muscle strength, and static balance in moderate sarcopenic older women. The diagnosis of sarcopenia was done in accordance with measurable variables and cut-off points suggested by the European Working Group on Sarcopenia in Older People (EWGSOP). Seventy-two participants were randomly assigned to two groups: the muscle reinforcement training group (RESISTANCE) (n=35; 69.9 ± 2.7 years) and the postural training group (POSTURAL) (n=37; 70.0±2.8 years). Body composition, muscle mass, skeletal muscle mass index (SMI), and handgrip strength (HGS) were evaluated for sarcopenia assessment, whereas Sway Path, Sway Area, Stay Time, and Spatial Distance were evaluated for static balance assessment. Sixty-six participants completed the study (RESISTANCE group: n=33; POSTURAL group: n=33). Significant increases of muscle mass, SMI, and handgrip strength values were found in the RESISTANCE group, after muscle reinforcement program. No significant differences appeared in the POSTURAL group, after postural training. Furthermore, RESISTANCE group showed significant improvements in static balance parameters, whereas no significant differences appeared in the POSTURAL group. On the whole, the results of this study suggest that the APA program based on muscle reinforcement applied on moderate sarcopenic older women was able to significantly improve muscle mass and muscle strength, and it was also more effective than the applied postural protocol in determining positive effects on static balance.


Asunto(s)
Terapia por Ejercicio , Fuerza Muscular/fisiología , Equilibrio Postural/fisiología , Entrenamiento de Fuerza , Sarcopenia/terapia , Anciano , Ejercicio Físico/fisiología , Femenino , Fuerza de la Mano/fisiología , Humanos , Músculo Esquelético/fisiología , Sarcopenia/fisiopatología
3.
Brain Res ; 1285: 158-63, 2009 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-19523930

RESUMEN

Phosphocreatine-Mg-complex acetate (PCr-Mg-CPLX) is a creatine-derived compound that in previous in vitro research was able to increase neuronal creatine independently of the creatine transporter, thus providing hope to cure the hereditary syndrome of creatine transporter deficiency. In previous research we showed that it reproduces in vitro the known neuroprotective effect of creatine against anoxic damage. In the present paper we investigated if PCr-Mg-CPLX reproduces this neuroprotective effect in vivo, too. We used a mouse model of transient middle cerebral artery occlusion. Mice received PCr-Mg-CPLX or a mixture of the two separate compounds phosphocreatine (PCr) and MgSO(4), or vehicle. The injections were done 60 min and 30 min before ischemia. Forty-eight hours after ischemia neurological damage was evaluated with Clark's behavioural tests, then the infarct volume was measured. PCr-Mg-CPLX reduced the infarct volume by 48%, an effect that was not duplicated by the separate administration of PCr and MgSO(4) and the neurological damage was decreased in a statistically significant way. We conclude that PCr-Mg-CPLX affords in vivo neuroprotection when administered before ischemia. These results are comparable to previous research on creatine administration in experimental stroke. PCr-Mg-CPLX maintains creatine-like neuroprotective effects in vivo as well as in vitro. Our study suggests that PCr-Mg-CPLX might have a therapeutic role in the treatment of hereditary creatine transporter deficiency and of conditions where there is a high risk of impending stroke or cerebral ischemic damage, like high-risk transient ischemic attacks, open heart surgery, and carotid surgery.


Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Creatina/metabolismo , Citoprotección/efectos de los fármacos , Magnesio , Degeneración Nerviosa/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Fosfocreatina/análogos & derivados , Fosfocreatina/farmacología , Animales , Infarto Encefálico/tratamiento farmacológico , Infarto Encefálico/fisiopatología , Infarto Encefálico/prevención & control , Isquemia Encefálica/metabolismo , Isquemia Encefálica/fisiopatología , Citoprotección/fisiología , Modelos Animales de Enfermedad , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Infarto de la Arteria Cerebral Media/metabolismo , Infarto de la Arteria Cerebral Media/fisiopatología , Masculino , Proteínas de Transporte de Membrana/deficiencia , Proteínas de Transporte de Membrana/efectos de los fármacos , Ratones , Degeneración Nerviosa/fisiopatología , Degeneración Nerviosa/prevención & control , Fármacos Neuroprotectores/uso terapéutico , Fosfocreatina/uso terapéutico , Resultado del Tratamiento
4.
Neuroscience ; 142(4): 991-7, 2006 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-16949212

RESUMEN

Hereditary creatine transporter deficiency causes brain damage, despite the brain having the enzymes to synthesize creatine. Such damage occurring despite an endogenous synthesis is not easily explained. This condition is incurable, because creatine may not be delivered to the brain without its transporter. Creatine-derived compounds that crossed the blood-brain barrier in a transporter-independent fashion would be useful in the therapy of hereditary creatine transporter deficiency, and possibly also in neuroprotection against brain anoxia or ischemia. We tested the double hypothesis that: (1) the creatine carrier is needed to make creatine cross the plasma membrane of brain cells and (2) creatine-derived molecules may cross this plasma membrane independently of the creatine carrier. In in vitro mouse hippocampal slices, incubation with creatine increased creatine and phosphocreatine content of the tissue. Inhibition of the creatine transporter with 3-guanidinopropionic acid (GPA) dose-dependently prevented this increase. Incubation with creatine benzyl ester (CrOBzl) or phosphocreatine-Mg-complex acetate (PCr-Mg-CPLX) increased tissue creatine content, not phosphocreatine. This increase was not prevented by GPA. Thus, the creatine transporter is required for creatine uptake through the plasma membrane. Since there is a strong indication that creatine in the brain is mainly synthesized by glial cells and transferred to neurons, this might explain why hereditary transporter deficiency is attended by severe brain damage despite the possibility of an endogenous synthesis. CrOBzl and PCr-Mg-CPLX cross the plasma membrane in a transporter-independent way, and might be useful in the therapy of hereditary creatine transporter deficiency. They may also prove useful in the therapy of brain anoxia or ischemia.


Asunto(s)
Encéfalo/metabolismo , Membrana Celular/metabolismo , Creatina/deficiencia , Proteínas de Transporte de Membrana/metabolismo , Neuronas/metabolismo , Animales , Transporte Biológico Activo/efectos de los fármacos , Transporte Biológico Activo/fisiología , Encéfalo/efectos de los fármacos , Encefalopatías Metabólicas/tratamiento farmacológico , Encefalopatías Metabólicas/metabolismo , Encefalopatías Metabólicas/fisiopatología , Membrana Celular/efectos de los fármacos , Creatina/análogos & derivados , Creatina/farmacología , Inhibidores Enzimáticos/farmacología , Guanidinas/farmacología , Masculino , Proteínas de Transporte de Membrana/efectos de los fármacos , Ratones , Ratones Endogámicos ICR , Neuronas/efectos de los fármacos , Técnicas de Cultivo de Órganos , Propionatos/farmacología
5.
Brain Res ; 1114(1): 187-94, 2006 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-16949559

RESUMEN

Although a large body of evidence shows that pretreatment of brain tissue with creatine protects against anoxic injury in vitro, only a couple of papers have investigated creatine protection in vivo, and they yielded conflicting results. We attempted to clarify how creatine may be protective in an in vivo model of global cerebral ischemia (GCI). We administered creatine either before of after GCI. We decided to administer it by intracerebroventricular infusion, to maximize its bioavailability to the brain. Our findings show that creatine is clearly protective in vivo when administered before ischemia. In that case, histological evaluation of damage was consistently improved in all regions examined, and neurological score was better in creatine-treated rats than in controls. When administered after ischemia, histology was improved in the hippocampus, while only a not significant trend toward improvement was observed in the cerebral cortex and in the caudo-putamen. Neurological score was not improved by creatine administration after GCI. Our findings show that creatine administration is protective in vivo. Such protection was clear in the case of pretreatment, and was present, to a lesser degree, when treatment was started after ischemia. Our results should encourage further research in the possible role of creatine therapy in neuroprotection.


Asunto(s)
Isquemia Encefálica/complicaciones , Infarto Cerebral/etiología , Infarto Cerebral/prevención & control , Creatina/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Animales , Modelos Animales de Enfermedad , Esquema de Medicación , Hipocampo/patología , Inyecciones Intraventriculares/métodos , Masculino , Examen Neurológico , Neuronas/efectos de los fármacos , Neuronas/patología , Ratas , Ratas Sprague-Dawley , Índice de Severidad de la Enfermedad , Factores de Tiempo
6.
Amino Acids ; 23(1-3): 221-9, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12373542

RESUMEN

Phosphocreatine can to some extent compensate for the lack of ATP synthesis that is caused in the brain by deprivation of oxygen or glucose. Treatment of in vitro rat hippocampal slices with creatine increases the neuronal store of phosphocreatine. In this way it increases the resistance of the tissue to anoxic or ischemic damage. In in vitro brain slices pretreatment with creatine delays anoxic depolarization (AD) and prevents the irreversible loss of evoked potentials that is caused by transient anoxia, although it seems so far not to be active against milder, not AD-mediated, damage. Although creatine crosses poorly the blood-brain barrier, its administration in vivo at high doses through the intracerebroventricular or the intraperitoneal way causes an increase of cerebral phosphocreatine that has been shown to be of therapeutic value in vitro. Accordingly, preliminary data show that creatine pretreatment decreases ischemic damage in vivo.


Asunto(s)
Isquemia Encefálica/metabolismo , Creatina/metabolismo , Hipoxia Encefálica/metabolismo , Neuronas/metabolismo , Fármacos Neuroprotectores/metabolismo , Fosfocreatina/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Barrera Hematoencefálica/fisiología , Glucosa/metabolismo , Hipocampo/citología , Hipocampo/metabolismo , Neuronas/patología , Oxígeno/metabolismo
7.
Planta ; 210(4): 551-62, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10787048

RESUMEN

The flagella of the green alga Scherffelia dubia are covered by scales which consist of acidic polysaccharides and glycoproteins. Experimental deflagellation results in the regeneration of flagella complete with scales. During flagellar regeneration, scales are newly synthesized in the Golgi apparatus, exocytosed and deposited on the growing flagella. Flagellar regeneration is dependent upon protein synthesis and N-glycosylation, as it is blocked by cycloheximide and partially inhibited by tunicamycin. Metabolic labeling with [35S]methionine/cysteine demonstrated that scale-associated proteins were not newly synthesized during flagellar regeneration, suggesting that the proteins deposited on regenerating flagella were drawn from a pool. Quantitative immunoelectron microscopy using a monospecific antibody directed against a scale-associated protein of 126 kDa (SAP126) revealed that the pool of SAP126 was primarily located at the plasma membrane, with minor labeling of the scale reticulum and trans-Golgi cisternae, both before deflagellation and during flagellar regeneration. Since SAP126 was sequestered during flagellar regeneration into secretory vesicles together with newly synthesized scales, it is concluded that the persistent presence of SAP126 in the trans-Golgi cisternae during scale biogenesis requires retrograde transport of the protein from the plasma membrane to the Golgi apparatus.


Asunto(s)
Eucariontes/metabolismo , Glicoproteínas/biosíntesis , Aparato de Golgi/metabolismo , Polisacáridos/biosíntesis , Animales , Membrana Celular/metabolismo , Membrana Celular/ultraestructura , Eucariontes/citología , Eucariontes/ultraestructura , Flagelos/metabolismo , Flagelos/ultraestructura , Glicoproteínas/metabolismo , Aparato de Golgi/ultraestructura , Microscopía Inmunoelectrónica , Peso Molecular , Proteínas de Plantas/biosíntesis , Proteínas de Plantas/química , Proteínas de Plantas/metabolismo , Polisacáridos/metabolismo
8.
Cell Motil Cytoskeleton ; 42(2): 114-24, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10215421

RESUMEN

While it is now recognised that transport within the endomembrane system may occur via membranous tubules, spatial regulation of this process is poorly understood. We have investigated the role of the cytoskeleton in regulating the motility and morphology of the motile vacuole system in hyphae of the fungus Pisolithus tinctorius by studying (1) the effects of anti-microtubule (oryzalin, nocodazole) and anti-actin drugs (cytochalasins, latrunculin) on vacuolar activity, monitored by fluorescence microscopy of living cells; and (2) the ultrastructural relationship of microtubules, actin microfilaments, and vacuoles in hyphae prepared by rapid-freezing and freeze-substitution. Anti-microtubule drugs reduced the tubular component of the vacuole system in a dose-dependent and reversible manner, the extent of which correlated strongly with the degree of disruption of the microtubule network (monitored by immunofluorescence microscopy). The highest doses of anti-microtubule drugs completely eliminated tubular vacuoles, and only spherical vacuoles were observed. In contrast, anti-actin drugs did not reduce the frequency of tubular vacuoles or the motility of these vacuoles, even though immunofluorescence microscopy confirmed perturbation of microfilament organisation. Electron microscopy showed that vacuoles were always accompanied by microtubules. Bundles of microtubules were found running in parallel along the length of tubular vacuoles and individual microtubules were often within one microtubule diameter of a vacuole membrane. Our results strongly support a role for microtubules, but not actin microfilaments, in the spatial regulation of vacuole motility and morphology in fungal hyphae.


Asunto(s)
Microtúbulos/fisiología , Sulfanilamidas , Vacuolas/fisiología , Citoesqueleto de Actina/efectos de los fármacos , Citoesqueleto de Actina/fisiología , Actinas/antagonistas & inhibidores , Actinas/fisiología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Movimiento Celular/efectos de los fármacos , Criopreservación , Citocalasina B/farmacología , Citocalasina D/farmacología , Dinitrobencenos/farmacología , Relación Dosis-Respuesta a Droga , Substitución por Congelación , Hongos/fisiología , Microscopía Electrónica , Microscopía Fluorescente , Microtúbulos/efectos de los fármacos , Microtúbulos/inmunología , Microtúbulos/ultraestructura , Nocodazol/farmacología , Tiazoles/farmacología , Tiazolidinas , Vacuolas/efectos de los fármacos , Vacuolas/ultraestructura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...